NEW YORK – Radiomics and OncoDNA on Monday said they will combine the two companies' expertise in machine learning-enabled analysis of medical images and molecular biomarker evaluation to improve the biological understanding and treatment of non-small cell lung cancer.
The two Belgian firms will collaborate within the prospective Measure Lung Cancer Biology and Treatment Response via Imaging trial, dubbed SALMON for short, in which Radiomics is hoping to validate its artificial intelligence-based medical imaging analysis technology and create a "radiomics atlas of oncogenic biomarkers." In this trial, which will begin recruiting patients in multiple countries starting next year, researchers are collecting biopsy samples and imaging data from NSCLC patients and will analyze oncogenic features and therapy response in tomography and CT scans.
The latest collaboration will bring in OncoDNA's molecular biomarker analysis capabilities into the trial. OncoDNA will sequence NSCLC patients' tissue and blood samples in the SALMON trial and track disease progression using biomarkers in circulating tumor DNA.
"We believe pairing Radiomics science with our technology platform will prove the value of combining technologies and result in a major step ahead for the development of new solutions for cancer treatment," OncoDNA CEO Bernard Courtieu said in a statement.